Covaxin booster improves efficacy against Delta, Omicron variants: ICMR study

The antibody response, clinical observations, viral load reduction and lung disease severity after virus challenge were observed, said the study.
Representational Image. (File Photo | AFP)
Representational Image. (File Photo | AFP)

NEW DELHI: A booster dose of Covaxin enhances vaccine effectiveness against the Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech said.

The protective efficacy of Hyderabad-based Bharat Biotech’s Covaxin following two and three-dose immunisations against the Delta variant and the efficacy of the Covaxin against Omicron variants were studied in a Syrian hamster model (animal model to study human-associated diseases), the study said.

The findings of the study have been published on June 14 on bioRxiv, a pre-print server and have not been peer reviewed.

The anti-Covid vaccine Covaxin is one of two anti-Covid vaccinations used in the national coronavirus immunisation programme, which began in January 2021.

The antibody response, clinical observations, viral load reduction and lung disease severity after virus challenge were observed, said the study conducted by the Indian Council of Medical Research - National Institute of Virology, Pune and the pharma company.

“In the Delta infection study, where we compared the protective response between the two and three-dose regimens, we could observe the advantage of the booster dose vaccination in the protection. Although the neutralising antibody levels were comparable among the groups, lung disease severity was found more reduced after the three-dose vaccination,” said Dr Pragya Yadav, one of the authors of the study, who was recently awarded for her contribution to developing vaccines against Covid-19 in India.

“The virus shedding and viral organ load were considerably reduced in both the two dose and three-dose immunised animals indicating the vaccine efficacy against Delta variant,” the study added.

In the second study in which the protective response was assessed against Omicron variants -- BA.1 and BA.2, following three-dose vaccinations, lesser virus shedding, lung viral load and lung disease severity were observed in the immunised groups in comparison to the placebo groups.

“The evidence from the present study shows that Covaxin booster immunisation tends to broaden the protective immune response and reduces disease severity against the Delta and Omicron variant infection,” it added.

Related Stories

No stories found.

X
The New Indian Express
www.newindianexpress.com